Merck Says Phase 3 KEYNOTE-564 Trial Evaluating KEYTRUDA, Anti-PD-1 Therapy, Met Its Key Secondary Endpoint Of Overall Survival
Portfolio Pulse from Benzinga Newsdesk
Merck's Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, an anti-PD-1 therapy, has met its key secondary endpoint of overall survival. Previously, the trial had met its primary endpoint of disease-free survival, reducing the risk of disease recurrence or death by 32% compared to placebo.
November 01, 2023 | 10:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck's successful KEYNOTE-564 trial results could potentially boost the company's stock in the short term.
The successful results from the KEYNOTE-564 trial indicate a positive development for Merck's product, KEYTRUDA. This could potentially lead to increased sales and revenues for the company, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100